[Form 4] ACHIEVE LIFE SCIENCES, INC. Insider Trading Activity

Rhea-AI Filing Summary

Achieve Life Sciences, Inc. reported an insider equity grant for its Chief Legal Officer on a Form 4. On 12/04/2025, the officer received a stock option to purchase 250,000 shares of common stock at an exercise price of $4.78 per share. The option is exercisable as of 12/04/2025 and has an expiration date of 12/04/2035.

According to the footnote, this option will vest as to one quarter of the total award on the first anniversary of October 20, 2025, and the remaining portion will vest in substantially equal monthly installments over 36 months, subject to continued service with the company on each vesting date. Following this grant, the officer beneficially owns 250,000 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Atkisson Erik

(Last) (First) (Middle)

22722 29TH DR SE

SUITE 100

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ACHIEVE LIFE SCIENCES, INC. [ ACHV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.78	12/04/2025		A		250,000		(1)	12/04/2035	Common Stock	250,000	$0	250,000	D

Explanation of Responses:

1. This option will vest as to 1/4 of the total award on the first anniversary of October 20, 2025, and thereafter in substantially equal monthly installments over 36 months, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Sandra Thomson as attorney-in-fact for Erik Atkisson	12/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Achieve Life Sciences (ACHV) report on this Form 4?

Achieve Life Sciences reported the grant of a stock option for 250,000 shares of common stock to its Chief Legal Officer on 12/04/2025.

What is the exercise price and term of the new Achieve Life Sciences (ACHV) stock option?

The stock option has an exercise price of $4.78 per share, became exercisable on 12/04/2025, and has an expiration date of 12/04/2035.

How does the 250,000-share stock option for ACHV’s Chief Legal Officer vest?

The option will vest as to 1/4 of the total award on the first anniversary of October 20, 2025, with the remainder vesting in substantially equal monthly installments over 36 months, subject to continued service.

What is the reporting person’s role at Achieve Life Sciences (ACHV)?

The reporting person is an officer of Achieve Life Sciences, serving as the company’s Chief Legal Officer.

How many derivative securities does the Achieve Life Sciences (ACHV) officer own after this transaction?

After this transaction, the officer beneficially owns 250,000 derivative securities (stock options) with direct ownership.